Eris Lifesciences Limited IPO Message Board (Page 22)

Fully apply Eris

Can you have figure of current Biding or subscription?

Eris LifeSciences IPO
Market Estimates of oversubscription: (Revised)

Category-wise:

1X QIB(Net) = 519.64Crs – assuming applications of 10KCrs. = 20X oversubscription

1X NII = 259.82Crs – assuming applications of 25KCrs. = 96X oversubscription

1X RII = 119,688 Forms – assuming 7L forms. = 5.85X oversubscription (applic-wise)
i.e. average 4.10shares per form

@eagleye
As we know NII portion wasn`t fully subscribed. now who will get that remaining portion : QIB or RII.

QIB will get that portion

face value 1, and impractical price band... company z very small as compared to Sun pharma but they kept very huge price even very higher than Sun pharma!!! and what do you mean by face value Re.1. they don''t want to give anything to public! cheating to public... don''t expect any return be wary and prevent ur loss... ideally it''s price should be 110-120 at face value Re.1 that too on higher side. Don''t buy..

Septa sir,good morning.
Eris life me applying & avoid?
App jaisa bolo .

very now and then this discussion on FV and MV crops up. What matters is EPS and Book value per share. Share splits normally result in reduction in FV. The market value then adjuts itself based on new EPS as number of shares have gone up and not because FV has reduced. Therefore FV of share has got little to do with valuation. In case of Eris there is only OFS and no fresh issue. Therefore EPS will not be impacted by dilution. If the company is successful in maintaining top line and bottom line growth of past , then,asking price is justified. Just like investors look for a bargain, the seller also looks for the best price. Problem comes when financials are mediocre and a high price is demanded.

Mr Gamble
It is easy to say ''Ha ha''
Face value always matters every thing
If face value is 10 and offer price is 600 do you think it makes no difference
It only for the purpose of dividend
You will get 10 times dividend and on split you get 10 shares in 600 i.e. 60 each
A very simple maths
You are quite responsible and knowledgeable
How can you misguide others
Best of luck in inventing

We shud be focusing more on B/V, rather than F/V.

Every now and then this discussion on FV and MV crops up. What matters is EPS and Book value per share. Share splits normally result in reduction in FV. The market value then adjuts itself based on new EPS as number of shares have gone up and not because FV has reduced. Therefore FV of share has got little to do with valuation. In case of Eris there is only OFS and no fresh issue. Therefore EPS will not be impacted by dilution. If the company is successful in maintaining top line and bottom line growth of past , then,asking price is justified. Just like investors look for a bargain, the seller also looks for the best price. Problem comes when financials are mediocre and a high price is demanded.

Septa sir
why you not comment on Eris lifescience ipo?

What''s kostak & GMP Eris ???

Apply Or Avoid ?

Septa Sir,

Please clear your stand and guide us....

Regards

Yes
I am also waiting septa sir.

its pop with below message, first applicant name its coming as default not sure why asking again.

"Please enter first applicant name"

Please advise how to resolve this problem.

There seems to be some problem with HDFC Sec site (may have some bug), even if order is thru it doesn''t appear in order book, hope they will sort out this problem by Monday morning

There is an error in applying using crome and other browsers. Use Internet Explorer and delet history and cookies, then try. Your problem will be solved.

Dear Admin,


Not update msg from this forum..change new formet not a good..so people misguide read old msg.pls chenge formet..

regard

Viraj.

Agree

High value ipo compare to other Indian pharma co. Premium is very high & nothing is left for you,instead something will move out of your pocket. Government policy do not favorable for pharma co.Coming days are for Generic pharma co.If i do not forget cadila ipo was list with negative figure. I lost some money on listing day.Company is asking high premium based on future performance but KAL KESNE DEKHA HE, If you relay love this ipo then buy from market at lesser price then ipo price. Many agency suggested to subscribed ipo but remember,S.Chand,ICICI ipo & LNT ipos. What did you get? Anchor list is good in all ipos but see the subscription figure of Tejus .Very poor.Lastly GMP decreased from 140 to 45-50 today.It is only 8 % gain as of today,but most recent ipo list with lesser rate then GMP ( S.Chand/Hudco & many).Do you expect ant listing gain ?, think your self before investing.AVOID & SAVE MONEY FOR CDSL.If I am wrong then sorry to hurt u.

As on 31.03.2016 from RHP (in CRS)
Co. Sale PE
GSK. 2891. 60.80
ABBOTT. 2679. 36.14
SANOFI. 2244. 29.09
PFIZER. 2103. 36.91
ERIS. 0600. 62.10

Is it justified premium / PE asked by Eris?
Is Eris a big company than Abbott or SANOFI, salewise or profitwise ?
There''s no control of SEBI over the premium to safeguard the investors.

From pg no 83 of RHP. Showing EPS 9.xx.

Well thats 6 months eps

Apply Or Avoid ?

Apply

Septa sir
Eris lifesciences me kya karna hai
Please tell..

Application sell price in ahmedabad??

Eris is the fastest growing company total revenue CAGR of 17% in
FY13-17 and CAGR of 29% in Chronic category over the same period.
Another positive about the company is that its EBITDA margins have
expanded to 37% in FY17 from 22% in FY13 led by focus on niche
segments within the chronic category. At upper price band of INR603, the
issue is available at 34x FY17 EPS which is at par with other listed players.
We remain positive on the company and we believe it deserves premium
valuation as 1) it is high growth story led by significant focus on lifestyle
related disorders, 2) significantly higher margins, 3) debt free status and 4)
superior return profile of 45%+ both ROEs and ROCEs. !!

Amunt blok ho gaya SMS nahe aya Bse ka app submit. Ka

Amunt blok ho gaya SMS nahe aya Bse ka app submit. Ka